13D Filings
NEWAMSTERDAM PHARMA COMPANY N.V.
NAMS
Amendment
Ownership

7.70%

Total Shares

8,623,939

Issuer CIK

1936258

CUSIP

N62509109

Event Date

Oct 31, 2025

Accepted

Nov 4, 2025, 05:23 PM

Reporting Persons (15)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
FHMLSP, L.L.C.
Other
7.70%8,623,93908,623,939
Frazier Life Sciences Public Fund, L.P.
Partnership
7.70%8,623,93908,623,939
FHMLSP, L.P.
Partnership
7.70%8,623,93908,623,939
Frazier Life Sciences X, L.P.
Partnership
6.50%7,329,85707,329,857
FHMLS X, L.P.
Partnership
6.50%7,329,85707,329,857
FHMLS X, L.L.C.
Other
6.50%7,329,85707,329,857
James N. Topper
Individual
6.50%7,329,85707,329,857
Patrick J. Heron
Individual
6.50%7,329,85707,329,857
Frazier Lifesciences Sponsor LLC
Other
3.50%3,968,00003,968,000
FHMLS XI, L.L.C.
Other
1.00%1,179,92601,179,926
Frazier Life Sciences XI, L.P.
Partnership
1.00%1,179,92601,179,926
FHMLS XI, L.P.
Partnership
1.00%1,179,92601,179,926
FHMLS XII, L.P.
Partnership
0.10%68,567068,567
Frazier Life Sciences XII, L.P.
Partnership
0.10%68,567068,567
FHMLS XII, L.L.C.
Other
0.10%68,567068,567
Disclosure Items (6)

Security Title

Ordinary Shares, nominal value EUR0.12 per share

Issuer Name

NEWAMSTERDAM PHARMA COMPANY N.V.

Issuer Address

Gooimeer 2-35, 1411, Naarden, P7, 1411 DC

Filing Persons

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences X, L.P. ("FLS X") Frazier Lifesciences Sponsor LLC ("Sponsor") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")

Business Address

The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 70 Willow Road, Suite 200 Menlo Park, CA 94025

Principal Occupation

Item 2(c) is hereby amended and restated in its entirety to read as follows: The Sponsor's principal business is to act as the sponsor of Frazier Lifesciences Acquisition Corporation, the Issuer's predecessor ("FLAC"), in connection with the initial public offering ("IPO") of FLAC and the Business Combination (as defined below). FLS X, FLS XI, FLSPF and FLS XII are venture capital funds concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS X. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS X, L.P. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner FHMLS XII, L.P. The principal business of the Members is to manage FLS X, FLS XI, FLSPF, FLSOF, FHMLS X, L.P., FHMLS XI, L.P., FHMLSP, L.P., FHMLSP Overage, L.P., FHMLS X, L.L.C., FHMLS XI, L.L.C., FHMLSP, L.L.C., FHMLS XII, L.L.C., and a number of affiliated partnerships with similar businesses. FLS X is also the sole member of the Sponsor and Mr. Topper serves as a manager of the Sponsor.

Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLS X, Sponsor, FLSPF, FLS XI and FLS XII was the source of the funds for their respective purchases reported on Exhibit 10.1. No part of the purchase price for such purchases was represented by funds or other consideration borrowed or otherwise obtained for the purpose of such acquisitions.

Percentage of Class

The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLS X directly holds 3,028,524 Ordinary Shares and 333,333 warrants ("Warrants") to acquire an equivalent number of Ordinary Shares (collectively, the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. Sponsor directly holds 3,801,000 Ordinary Shares and 167,000 Warrants (the "Sponsor Shares"). FLS X is the sole member of Sponsor. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the Sponsor Shares. FLSPF directly holds 8,623,939 Ordinary Shares (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 1,179,926 Ordinary Shares (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 68,567 Ordinary Shares (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g).

Transactions

Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.

Shareholders

Item 4 is hereby amended to remove references to the "FLSPOF Shares".

On November 1, 2025, FLSPF and Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") entered into a merger agreement, which resulted in FLSPOF merging with and into FLSPF. As a result of the merger, (i) FLSPF acquired 2,989,476 Ordinary Shares of the Issuer from FLSPOF and (ii) FLSPOF, FHMLSP Overage, L.P., FHMLSP Overage, L.L.C. ceased being Reporting Persons under the Schedule 13D.

Exhibit 10.1 Transactions Relating to the Ordinary Shares of the Issuer During the Past Sixty (60) Days Exhibit 99.1 Joint Filing Agreement

NEWAMSTERDAM PHARMA COMPANY N.V. — Schedule 13D | 13D Filings